Money and murder: the dark side of the Asilomar meeting on recombinant DNA
By Matthew Cobb,
Nature
| 02. 17. 2025
On 24 February 1975, some 150 people met at the Asilomar Conference Grounds near Monterey on the Californian coast. They were mostly scientists from the United States, together with representatives of various companies and government agencies, and 16 journalists. Their subject was the new technology of recombinant DNA — molecules created in a laboratory by stitching together genetic material from different organisms. Researchers were excited by the possibilities for discoveries, and the potential of the technique to produce drugs, for example using specially engineered bacteria to make insulin. But they were also terrified that they might inadvertently create diseases that could infect lab workers and the wider community.
By the end of the meeting, its participants had agreed to adopt biosafety protocols that are still in force in the United States, and which have hugely influenced similar regulations worldwide. The meeting has become known simply as Asilomar, a byword for how a scientific community came together to forge consensus on a thorny topic. It is often held up as an example of how science can self-regulate without the involvement of...
Related Articles
By Angus Liu, Fierce Pharma | 02.21.2025
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez.
The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the...
By Angelica Peebles, CNBC | 02.21.2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was...
By Smriti Mallapaty, Nature | 02.20.2025
A two-and-a-half-year-old girl shows no signs of a rare genetic disorder, after becoming the first person to be treated for the motor-neuron condition while in the womb. The child’s mother took the gene-targeting drug during late pregnancy, and the child...
By Staff, GMWatch | 02.24.2025
In an open statement, civil society groups, scientists, and academics are challenging the democratic legitimacy of any conclusions or policy proposals that may arise from the 2025 Spirit of Asilomar and the Future of Biotechnology conference currently running from 23-26...